Stockscreener 앱 받기
28.12
5.24%
1.40
시장 영업 전:
28.55
0.43
+1.53%
전일 마감가:
$26.72
열려 있는:
$26.99
하루 거래량:
612.32K
Relative Volume:
0.65
시가총액:
$2.95B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.00%
1개월 성능:
+9.63%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$26.12
$29.20
1주일 범위
$25.47
$29.78
52주 변동 폭
$12.30
$32.81
Metsera Inc Stock (MTSR) Company Profile
명칭
Metsera Inc
전화
(212) 784-6595
주소
3 WORLD TRADE CENTER, NEW YORK
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
28.12 | 2.92B | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-25 | 개시 | BofA Securities | Buy |
| 2025-02-25 | 개시 | Evercore ISI | Outperform |
| 2025-02-25 | 개시 | Guggenheim | Buy |
Metsera Inc 주식(MTSR)의 최신 뉴스
Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership - insights.citeline.com
Metsera (NASDAQ:MTSR) Trading Down 6.9% – Here’s What Happened - Defense World
Cantor Fitzgerald maintains overweight on Metsera shares By Investing.com - Investing.com India
Cantor Fitzgerald maintains overweight on Metsera shares - Investing.com
Viking among notable gainers as Pfizer raises deal prospects - MSN
Two new option listings and two option delistings on May 22nd - TipRanks
Metsera Inc (NASDAQ: MTSR) Shares Rose Recently, But Trouble Could Still Be Around The Corner. - Stocksregister
Transcript : Metsera, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 02 - marketscreener.com
Decoding Metsera Inc (MTSR): A Strategic SWOT Insight - GuruFocus
Metsera's Q1 Net Loss Narrows - marketscreener.com
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress - The Manila Times
Metsera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise (NASDAQ:MTSR) - Seeking Alpha
Metsera to Present at Bank of America 2025 Global Healthcare Conference - The Manila Times
Metsera Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Metsera Rings the Opening Bell - Nasdaq
Metsera Inc’s Market Journey: Closing Weak at 22.74, Down -5.17 - DWinneX
MTSR Shares Experience Surge in Value - knoxdaily.com
Nothing is Better Than Metsera Inc (MTSR) stock at the moment - Sete News
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Metsera Inc. appoints new director and legal officer By Investing.com - Investing.com India
Metsera Inc. appoints new director and legal officer - Investing.com
A Guide To The Risks Of Investing In Metsera Inc (MTSR) - knoxdaily.com
Metric Analysis: Metsera Inc (MTSR)’s Key Ratios in the Limelight - DWinneX
A Closer Look at Metsera Inc (MTSR) Stock Gains - investchronicle.com
Metsera Inc (MTSR) stock analysis: A simple moving average approach - uspostnews.com
Metsera, Inc. Appoints New Board Member and Legal Officer - TipRanks
Metsera (NASDAQ:MTSR) Shares Gap Up – Time to Buy? - Defense World
Now Is The Time To Build A Position In Metsera Inc (NASDAQ:MTSR) - Marketing Sentinel
Metsera Inc [MTSR] Director makes an insider purchase of 2,222,222 shares worth 40.0 million. - knoxdaily.com
The Psychology of Metsera Inc Inc. (MTSR) Price Performance: Understanding Market Sentiment - investchronicle.com
Taking the lead: Metsera Inc (MTSR) - Sete News
Financial Metrics Exploration: Understanding Metsera Inc (MTSR) Through Ratios - DWinneX
How did Metsera Inc (MTSR) fare last session? - uspostnews.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
Lilly stock up rallying Structure and Metsera (GPCR:NASDAQ) - Seeking Alpha
Viking, Structure, Metsera on a tear as Pfizer drops obesity pill - MSN
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
Is it possible to buy Metsera Inc(MTSR) shares at a good price now? - uspostnews.com
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com - Investing.com South Africa
Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025 - Endpoints News
Metsera sees cash runway into 2027 - TipRanks
Metsera reports Q4 EPS ($3.52) vs. (94c) last year - TipRanks
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
6.48%
자본화:
|
볼륨(24시간):